With the right payment integrity approach and finely tuned focus, payers will find the exceptional service execution required to thrive in today’s environment.
Transformative AI to revamp prior authorizations Read More »
Devyser Diagnostics AB announced that the company has signed an exclusive collaboration and distribution agreement with Thermo Fisher Scientific.
Samsung Biologics, the world’s leading contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2023.
Samsung Biologics Reports First Quarter 2023 Financial Results Read More »
Everest Medicines announced that Nefecon, the first-in-disease treatment for primary immunoglobulin A nephropathy, has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary.
Zylox-Tonbridge Medical Technology Co., Ltd. announced the signing of a strategic agreement with Guangdong Hicicare Science Co., Ltd. With the collaboration, Zylox-Tonbridge and Hicicare plan to introduce and help accelerate the commercialization of co-branded vascular guidewire products in the neuro- and peripheral-vascular interventional device market segments in a move to provide innovative vascular access solutions
Net sales amounted to SEK 140.6 million, corresponding to an increase of 52 percent in SEK and 39 percent adjusted for currency effects.
XVIVO Presents Interim Report January-March 2023 Read More »
MaaT Pharma reported that the U.S. Food and Drug Administration has lifted the clinical hold and cleared the Investigational New Drug application to initiate in the U.S. an open-label, single arm Phase 3 pivotal clinical trial evaluating the safety and efficacy of MaaT013 to treat gastrointestinal acute Graft-versus-Host Disease as a third line of treatment.
Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce it will host a symposium at the 3rd ISIET’s International Symposium on Inner Ear Therapeutics, an event sponsored by Sensorion, taking place on April 28-30, 2023, in Marrakech, Morocco.
Belief BioMed Group announced the completion of patient dosing in its Phase III Registrational Clinical Trial of BBM-H901, a gene therapy for Hemophilia B developed and manufactured in-house by Shanghai Belief-Delivery Biomed Co., Ltd., its wholly owned subsidiary.
Bridge Biotherapeutics announced that it received notice from the U.S. Food and Drug Administration that it may proceed with the first-in-human study of BBT-207, which has the potential to be a mutant selective and broad-spectrum fourth-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for the treatment of non-small cell lung cancer.
